ARGFXP2

Across TCGA pan-cancer cohorts, ARGFXP2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ARGFXP2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ARGFXP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARGFXP2 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

COAD, KIRC, and CHOL are the cancer types where ARGFXP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARGFXP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	II,III,IV	+0.270	<.001	10	view →
KIRC	All	II,III,IV	+0.118	<.001	10	view →
CHOL	All	All	+0.374	<.001	4	view →
BLCA	All	All	+0.223	.021	4	view →
HNSC	All	II,III,IV	+0.077	.014	4	view →
LIHC	All	All	+0.035	.010	4	view →
READ	All	III,IV	+0.424	.011	3	view →
STAD	All	All	+0.252	.035	3	view →
THCA	All	All	−0.083	.001	3	view →
LUAD	All	All	+0.259	.042	1	view →
KIRP	All	All	+0.097	.016	1	view →
LUSC	Female	III,IV	−0.095	.013	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ARGFXP2–COAD

Open the COAD breakdown →